| Literature DB >> 29610200 |
Abstract
Enterococcus faecalis is an opportunistic pathogen and leading cause of health care-associated infections. Daily chlorhexidine gluconate (CHG) bathing of patients is generally regarded as an effective strategy to reduce the occurrence of health care-associated infections. It is likely that E. faecalis is frequently exposed to inhibitory and subinhibitory concentrations of CHG in clinical settings. The goal of this study was to investigate how the vancomycin-resistant strain E. faecalis V583 transcriptionally responds to and tolerates stress from CHG. We used transcriptome (microarray) analysis to identify genes upregulated by E. faecalis V583 in response to CHG. The genes efrE (EF2226) and efrF (EF2227), encoding a heterodimeric ABC transport system, were the most highly upregulated genes. efrEF expression was induced by CHG at concentrations several 2-fold dilutions below the MIC. Deletion of efrEF increased E. faecalis V583 susceptibility to CHG. We found that ChlR, a MerR-like regulator encoded by a sequence upstream of efrEF, mediated the CHG-dependent upregulation of efrEF, and deletion of chlR also increased chlorhexidine susceptibility. Overall, our study gives insight into E. faecalis stress responses to a commonly used antiseptic.Entities:
Keywords: Enterococcus; chlorhexidine
Mesh:
Substances:
Year: 2018 PMID: 29610200 PMCID: PMC5971576 DOI: 10.1128/AAC.00267-18
Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN: 0066-4804 Impact factor: 5.191
FIG 1Growth curves. (a) The optical density at 600 nm (OD600) is shown on the y axis. Mid-exponential-phase E. faecalis V583 cultures (OD600, 0.4 to 0.5) were split into fresh, prewarmed medium to achieve different H-CHG concentrations (indicated with the arrow). For all experiments, 1× MIC is the broth microdilution MIC of E. faecalis V583. The time point at which RNA was harvested is also indicated. (b) Viable cell counts (number of CFU per milliliter) for 1× MIC-treated cultures and control cultures are shown. For this curve, the time at which cultures were split is set to 0 h. For both panels, error bars indicate standard deviations from 3 independent experiments.
FIG 2Quantitative RT-PCR confirms H-CHG-dependent upregulation of efrF. Primers were designed to amplify ∼600-bp internal regions of efrF. RNA was harvested from E. faecalis V583 after 15 min of exposure to no CHG, 1/2× MIC H-CHG, or 1× MIC H-CHG. The gyrase B (gyrB) gene was amplified as a control. *, P < 0.05; **, P < 0.005; ***, P < 0.0005.
FIG 3efrEF and chlR deletion mutants are more susceptible to H-CHG. Overnight cultures were adjusted to an OD600 of ∼0.3 and serially diluted in 10-fold dilutions. Ten microliters of each dilution (from 10−1 to 10−6, from left to right in each image) was spotted on BHI agar supplemented with different concentrations of H-CHG. The images are representative of those from three independent trials. The results of experiments assessing the contributions of efrEF (a) and chlR (b) to chlorhexidine susceptibility are shown.
FIG 4chlR is required for H-CHG-dependent upregulation of efrF. Quantitative RT-PCR was used to investigate efrF expression in cultures of wild-type strain V583, the ΔchlR mutant, the ΔchlR mutant with the empty complementation vector pCAT28, and the complemented ΔchlR strain (ΔchlR/pFL102) after 15 min of exposure to 1/2× MIC H-CHG or no H-CHG. The gyrase B (gyrB) gene was amplified as a control. *, P < 0.05.
FIG 5Organization of chlR-efrE intergenic region. The organization of the chlR and efrEF genes is shown (the arrows are not drawn to scale). Transcription start sites (TSS) were detected 33 and 78 bp upstream of the efrE ORF. Consensus −35 and near-consensus −10 housekeeping sigma factor promoter sequences upstream of the H-CHG-responsive efrE promoter (P) are shown in bold. Putative ChlR binding motifs are underlined. The predicted promoter for the −78-bp TSS is not shown for clarity.
FIG 6β-Galactosidase assays. Cultures were spotted on BHI agar plates supplemented with X-Gal and different concentrations of H-CHG. Wild-type V583 with pPB101 (promoterless lacZ) was used as the negative control for all panels. (a) efrE promoter activity (pFL201) in wild-type V583 and the ΔchlR strain. (b) chlR promoter activity (pFL202) in wild-type V583 and the ΔchlR strain. (c) efrE promoter activity in wild-type V583 with (pFL204) or without (pFL203) mutation of the 3′ region of the putative ChlR binding motif. The images shown are representative of those from three independent trials.
Bacterial strains and plasmids used in this study
| Strain or plasmid | Description | Reference or source |
|---|---|---|
| Bacterial strains | ||
| | ||
| V583 | Bloodstream isolate; VanB-type VRE | |
| OG1RF | Human oral isolate | |
| Δ | This study | |
| Δ | This study | |
| Δ | This study | |
| FL101 | This study | |
| FL201 | This study | |
| FL202 | This study | |
| FL203 | This study | |
| FL204 | This study | |
| Δ | Δ | This study |
| Δ | Δ | This study |
| Δ | Δ | This study |
| | ||
| EC1000 | Cloning host; provides | |
| DH5α | Cloning host; F−
| |
| BW23474 | Cloning host for pPB101 and derivatives; Δ | |
| Plasmids | ||
| pHA101 | pLT06 plasmid with | |
| pCAT28 | Shuttle vector; pUC and pAMβ1 origins; confers chloramphenicol resistance | M. Rodrigues and K. Palmer |
| pFL102 | pCAT28 containing 882-bp EcoRI/BamHI-digested | This study |
| pFL103 | pCAT28 containing 3,673-bp EcoRI/BamHI-digested | This study |
| pPB101 | pTCV-lac-cat; expression vector for Gram-positive bacteria; confers kanamycin, erythromycin, and chloramphenicol resistance | |
| pFL201 | pPB101 with 114-bp EcoRI/BamHI-digested | This study |
| pFL202 | pPB101 with 114-bp EcoRI/BamHI-digested | This study |
| pFL203 | pPB101 with 98-bp EcoRI/BamHI-digested | This study |
| pFL204 | pPB101 with 98-bp EcoRI/BamHI-digested | This study |